Aspire Biopharma Furnishes Press Release Under Regulation FD (Sep 8, 2026)

What Happened
Aspire Biopharma Holdings, Inc. (ASBP) filed a Form 8-K on September 8, 2026, reporting a Regulation FD disclosure. The filing furnishes a company press release dated September 8, 2026, which is attached as Exhibit 99.1 and incorporated by reference.

Key Details

• Filing date: September 8, 2026 (Form 8-K).
• Item reported: 7.01 — Regulation FD Disclosure.
• Exhibit included: 99.1 — Press Release dated September 8, 2026.
• Administrative exhibit: 104 — Cover Page Interactive Data File (Inline XBRL).

Why It Matters
A Regulation FD disclosure means Aspire publicly shared information via a press release; that release could contain material news such as corporate updates, clinical or commercial developments, or financial information. The 8-K itself does not summarize the release — investors should review Exhibit 99.1 (available on the SEC EDGAR site or the company’s investor relations page) to see if the news affects ASBP’s outlook or investment thesis.